Announcement of establishment of CMC laboratory and appointment of Head of CMC

LUCA Science Inc. (Headquarters: Chuo-ku, Tokyo) has opened its own research laboratory of the CMC department in Shinkiba, Tokyo, and is pleased to announce that Tomoyuki Inoue has been appointed as Head of CMC.

At the laboratory, we will proceed with the establishment of manufacturing process and assay methods based on our novel mitochondria isolation technology platform, and further promote accelerate research and development for IND open with our own pipeline.

Comment from Tomoyuki Inoue

It is indispensable to enhance engineering capabilities based on integration of conventional technologies in order to release a novel therapeutic modality, organelle drug product, into world. We’ll keep efforts on it and collaborate with other parties as appropriate to succeed in establishment of manufacturing process and assay methods as early as possible so that this new product can satisfy some unmet medical needs and be an option for the people who need novel therapeutic methods.

Profile Tomoyuki Inoue, Ph.D.

Tomoyuki started his career from Tsukishima Kikai Co., Ltd. After studying at the University of Stuttgart in Germany, he experienced the development of biopharmaceutical manufacturing process at Chugai Pharmaceutical Co., Ltd. Since 2014, he has led the GMP manufacturing and development of iPS cell-derived platelet products as the CMC manager at Megakaryon Corporation, and achieved the IND open in JP. Since February 2022, he has been appointed as Head of CMC at LUCA Science Inc.